What smart money is saying about Lumos Diagnostics
1 fund in our archive has pitched Lumos Diagnostics — most recently Ryder Capital Limited in September 2026.
Lumos Diagnostics Holdings Limited develops, manufactures, and distributes diagnostic technologies in the United States. The company offers FebriDx, a point-of-care diagnostic test for acute respiratory infections, and ViraDx, a three-in-one point-of-care test for influenza A, influenza B, and COVID-19. It also provides assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. The company was incorporated in 2018 and is headquartered in Carlsbad, California.
Get an email when a fund buys, sells or pitches it
Position history
Every position in Lumos Diagnostics on record in the archive was reported in Q3 2026, across 1 fund letter — 1 opened or added to the position.
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 1 | 1 | 0 | 1 |
Fund activity · 1 position · 1 move
- AddedRyder Capital LimitedSeptember 2026
“Lumos Diagnostics – 5.00% Portfolio Weight Lumos eased 4.8% over the quarter as the share price consolidated around 10 cents. Following receipt of CLIA Waiver in March for its unique FebriDX point of care product, the business has used the quiet North American summer flu and respiratory infection season to focus on commercial development, with strong customer and insurance/reimbursement support assisting in building out a customer network of healthcare sites in advance of the US winter flu season. Lumos is debt free with US$15.4m of cash at 30 June. In September we exercised our 13.7m options at 7 cents per share, increasing our holding at an attractive price.”
Lumos Diagnostics
Fund coverage · 1 thesis
- Ryder Capital LimitedSeptember 2026
Lumos Diagnostics has a CLIA-waived point-of-care product, reimbursement support, and a cash-rich balance sheet that may help commercial rollout.
Read the full thesis
Read every full thesis on Lumos Diagnostics
Unlock all 1 thesis — the full reasoning behind what funds are buying, plus unlimited access to the entire archive.
View plans→